Co-expression of Programmed Death Ligand 1 (PD-L1) and markers of Epithelial-Mesenchymal Transition (EMT) on Circulating Tumor Cells (CTCs): a possible immune escape mechanism in urothelial carcinomas of the urinary bladder.
cun id:
1344
MEDICINA PERSONALIZZATA
The role of KMT2C, a chromatin-modifying and remodelling protein, in osteosarcoma metastatic progression.
A Clinically Validated Cohort of Type 2 Diabetes Mellitus Virtual Patients on insulin therapy
VALUTAZIONE CLINICA E PROGNOSTICA DELL'INDICE DI PROLIFERAZIONE Ki67 E DEL PROTO-ONCOGENE HER-2/neu NEL CARCINOMA DIFFERENZIATO DELLA TIROIDE
A multimethodological pilot study to develop personalized diets including functional plant food/beverages and appropriate physical training, for young obese adults
Easy-to-access assay for Circulating Tumor Cell count: a potential tool a tailored therapeutic strategy in castration-resistant prostate cancer patients with bone metastases.
Novel epigenetic therapeutic strategies in rhabdomyosarcoma.
Urinary mutant DNA (mutDNA) as non-invasive biomarker in non-muscle invasive bladder cancer (NMIBC)
Liquid biopsy for precision medicine in RAS mutant colorectal cancer patients relapsed after first line therapy
The effect of systemic hormone replacement therapy on quality of life and short-term breast cancer risk in BRCA mutated patients after prophylactic salpingo-oophorectomy: a prospective study.